No Data
HEC CJ PHARM: Interim Report 2024
Not afraid of the sector's 'black swan' contra-market rise, HEC CJ Pharm (01558) accelerated the release of its in-market value.
On September 10th, the Biosecure Act (Bill HR 8333) in the United States caused turbulence in the Hong Kong stock biopharmaceutical sector, affecting many stocks. However, there are also stocks that have risen against the external environment, including HEC CJ Pharm (Symbol 01558).
HK stocks | Hec CJ Pharm (01558) rose by nearly 4%, officially included in the list of Hong Kong Stock Connect from today. Insulin operating revenue in the first half of the year increased significantly year-on-year.
Hec CJ Pharm (01558) rose nearly 4% in early trading. As of the time of writing, it is up 3.67% to HKD 9.04, with a turnover of HKD 17.7639 million.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
Hec CJ Pharmacy (01558.HK) has diversified business lines that drive performance, and the anti-influenza drug Keweipin brand has been upgraded.
In the current market environment dominated by uncertainty, whether it is Hong Kong stocks or A-share investors, their conditions for choosing investment targets or industries have shifted to stable businesses, profits, and stable cash flow generation capabilities. In short, "stability is everything", and previously popular dividend stocks and public utility stocks are simply classic examples of the "stability paradigm". Recently, a brokerage research report believes that with policy improvements and optimization of centralized procurement rules, centralized procurement risks are decreasing, and the generic drug market is expected to expand due to the expiration of patent medicines, bringing investment opportunities for generic drug companies. These companies are stable.
Earnings Are Growing at YiChang HEC ChangJiang Pharmaceutical (HKG:1558) but Shareholders Still Don't Like Its ProspectsNo Data
No Data
